| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 03/14/2002 | US20020032206 Pharmaceutical compositions for prevention and treatment of central nervous system disorders |
| 03/14/2002 | US20020032205 An alkyl amine substituted isobenzofuran compound useful for certain psychiatric and neurological disorders; potently binding to the 5-HT1A receptor |
| 03/14/2002 | US20020032204 Reacting a substituted indol-2-one compound with an acyclic or cyclic amine free of piperidine-1-yl or morpholine-4-yl to form protein kinase inhibitor |
| 03/14/2002 | US20020032199 5-HT7 receptor antagonists |
| 03/14/2002 | US20020032197 Methods and compositions for using moclobemide |
| 03/14/2002 | US20020032196 CRF receptor antagonists and methods relating thereto |
| 03/14/2002 | US20020032194 CRF receptor antagonists and methods relating thereto |
| 03/14/2002 | US20020032191 6-phenylpyridyl-2-amine derivatives useful as NOS inhibitors |
| 03/14/2002 | US20020032185 Agent for treating parkinson's disease comprising astrocyte function-improving agent as active ingredient |
| 03/14/2002 | US20020032183 Use of (di-substituted-phenyl)-pyrimidinyl-imidazole derivatives as JNK-inhibitors |
| 03/14/2002 | US20020032169 Aminosugar, glycosaminoglycan, and S-adenosylmethionine composition for the treatment and repair of connective tissue |
| 03/14/2002 | US20020032151 Using an agent which promotes tyrosine protein dephosphorylation in the preparation of a medicament for reducing permeability of a physiological barrier such as the blood-brain barrier |
| 03/14/2002 | US20020031800 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 03/14/2002 | US20020031792 Complexing with monoclonal antibodies |
| 03/14/2002 | US20020031560 Stabilized St. John's wort; antidepressant |
| 03/14/2002 | US20020031507 Treatment of inflammatory processes of the intestine, hypercholesterolaemia and infections with Helicobacter pylori; anticarcinogenic agent |
| 03/14/2002 | US20020031497 Porcine neural cells and their use in treatment of neurological deficits due to neurodegenerative diseases |
| 03/14/2002 | US20020031480 Aerosolizing a hydrofluoroalkane (HFA)/THC composition to provide droplets respirable by a lung of a patient, and administering; inhalers; treating pain, cachexia, migraines, nausea,muscle spasticity |
| 03/14/2002 | DE10043702A1 New antisense oligonucleotides and ribozymes, useful for treating e.g. pain and for diagnosis, are directed against mRNA for vanilloid-family receptors |
| 03/14/2002 | DE10042137A1 sgk2 und sgk3 als diagnostische und therapeutische Targets sgk2 and sgk3 as diagnostic and therapeutic targets |
| 03/14/2002 | DE10041479A1 Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923 Novel pharmaceutical composition for the administration of N-0923 |
| 03/14/2002 | DE10041478A1 Neue pharmazeutische Zusammensetzung New pharmaceutical composition |
| 03/14/2002 | DE10040901A1 Neue Phenyl- und Phenylalkyl-substituierte Ethanolamine und Ethylendiamine New phenyl and phenylalkyl substituted ethanolamines and ethylenediamines |
| 03/14/2002 | DE10023486C1 Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel Ortho-substituted anthranilic acid amides and their use as medicaments |
| 03/14/2002 | CA2422198A1 Substituted hydrazine derivatives |
| 03/14/2002 | CA2421922A1 Proteases |
| 03/14/2002 | CA2421912A1 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 03/14/2002 | CA2421842A1 Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders |
| 03/14/2002 | CA2421760A1 G-csf analog compositions and methods |
| 03/14/2002 | CA2421757A1 G-csf analog compositions and methods |
| 03/14/2002 | CA2421380A1 Biopanning and rapid analysis of selective interactive ligands (brasil) |
| 03/14/2002 | CA2421374A1 Methods and compositions for diseases associated with amyloidosis |
| 03/14/2002 | CA2421324A1 Mutant non-human mammal for expressing the alpha6 acetylcholine nicotinic receptor subunit and use for screening substances capable of interacting with said receptor |
| 03/14/2002 | CA2421271A1 Human and mouse targeting peptides identified by phage display |
| 03/14/2002 | CA2421213A1 The hydrochloride salt of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione |
| 03/14/2002 | CA2421200A1 Adenoviral targeting and manipulation of immune system response using targeting peptides |
| 03/14/2002 | CA2421195A1 Compositions and methods for targeting peptides in humans in vivo |
| 03/14/2002 | CA2421191A1 Methods and compositions for in vitro targeting |
| 03/14/2002 | CA2421172A1 Gamma-ketoacid dipeptides as inhibitors of caspase-3 |
| 03/14/2002 | CA2421027A1 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 03/14/2002 | CA2419966A1 Aryl substituted tetrahydroindazoles and their use as ligands for the gaba-a receptor |
| 03/14/2002 | CA2419958A1 Substituted fused pyrroleimines and pyrazoleimines |
| 03/14/2002 | CA2419456A1 Methods and compositions for producing a neurosalutary effect in a subject |
| 03/14/2002 | CA2417177A1 Spiroheterocyclic nitriles useful as reversible inhibitors of cysteine proteases |
| 03/13/2002 | EP1186617A1 Novel recombinant antibody, amino acid sequences of cdrs thereof and genes encoding the same |
| 03/13/2002 | EP1186615A1 Novel protein and dna thereof |
| 03/13/2002 | EP1186594A1 N-alkoxyalkyl-n,n-dialkylamine derivatives or salts thereof, and remedies for nerve degeneration diseases containing the same |
| 03/13/2002 | EP1186318A2 Combination, for treating depression and anxiety, containing a 5HT1d receptor antagonist and aCNS penetrant NK-1 receptor antagonist |
| 03/13/2002 | EP1186304A2 Pharmaceutical combinations for the treatment of stroke and traumatic brain injury |
| 03/13/2002 | EP1186296A1 Mag expression promoters |
| 03/13/2002 | EP1185700A1 49 human secreted proteins |
| 03/13/2002 | EP1185694A1 49 human secreted proteins |
| 03/13/2002 | EP1185649A2 The myostatin gene promoter and inhibition of activation thereof |
| 03/13/2002 | EP1185632A1 Caspase-8 crystals, models and methods |
| 03/13/2002 | EP1185555A2 Compositions isolated from skin cells and methods for their use |
| 03/13/2002 | EP1185552A1 Retro-inverso peptides derived from interleukin-3 |
| 03/13/2002 | EP1185549A2 Dna encoding a human subunit of the 5-ht3 serotonin receptor |
| 03/13/2002 | EP1185543A1 50 human secreted proteins |
| 03/13/2002 | EP1185542A2 Purine derivatives |
| 03/13/2002 | EP1185532A1 Peroxynitrite decomposition catalysts and methods of use thereof |
| 03/13/2002 | EP1185530A1 Imidazo- and pyrrolo[1,2-a]pyrimid-4-ones as gonadotropin-releasing hormone receptor antagonists |
| 03/13/2002 | EP1185528A1 Inhibitors of il-12 production |
| 03/13/2002 | EP1185524A2 3-heteroarylalkyl substituted gaba analogs |
| 03/13/2002 | EP1185521A1 Substituted 1-aza-2-imino-heterocycles and their use as activators of nicotinic acetylcholine receptors |
| 03/13/2002 | EP1185516A1 Substituted phenylcyclohexane carboxylic acid amides that have an adenosine uptake inhibiting effect |
| 03/13/2002 | EP1185515A1 Method of inhibiting neurotrophin-receptor binding |
| 03/13/2002 | EP1185514A1 Pharmaceutical compositions and methods for use |
| 03/13/2002 | EP1185513A2 Aryl substituted alkylamines capable of activating nicotinic cholinergic receptors |
| 03/13/2002 | EP1185316A1 Devices and compounds for treating arterial restenosis |
| 03/13/2002 | EP1185304A2 Conjugates comprising cytokines and nucleic acids for treating proliferating cells |
| 03/13/2002 | EP1185302A2 Specifically targeted catalytic antagonists and uses thereof |
| 03/13/2002 | EP1185298A2 Prevention and treatment of amyloidogenic disease |
| 03/13/2002 | EP1185296A2 Prevention and treatment of amyloidogenic disease |
| 03/13/2002 | EP1185294A2 Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders |
| 03/13/2002 | EP1185293A2 Il6ril6 chimera for the treatment of neurodegenerative diseases |
| 03/13/2002 | EP1185291A2 Therapeutic agent comprising a botulinum neurotoxin |
| 03/13/2002 | EP1185286A1 Mu o-conopeptides and their use as local anesthetics |
| 03/13/2002 | EP1185284A1 47 human secreted proteins |
| 03/13/2002 | EP1185276A1 Isophosphoramide mustard analogs and use thereof |
| 03/13/2002 | EP1185272A2 Novel use of 1-[4-(5-cyanoindol-3yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine and its physiological acceptable salts |
| 03/13/2002 | EP1185271A1 Il-8 receptor antagonists |
| 03/13/2002 | EP1185268A1 The therapeutic use of d-threo-methylphenidate for the treatment of attention-deficit hyperactivity disorder |
| 03/13/2002 | EP1185263A2 Receptor agonists and antagonists |
| 03/13/2002 | EP1185259A1 Glycine cleavage system inhibitors as potential antipsychotics |
| 03/13/2002 | EP1185246A1 Pharmaceutical composition for intranasal use of active substances that are insoluble and/or hardly soluble in water |
| 03/13/2002 | EP1185171A1 Compositions and methods comprising morphine gluconate |
| 03/13/2002 | EP1041988A4 A method of preventing abuse of opioid dosage forms |
| 03/13/2002 | EP0946157B1 The topical use of kappa opioid agonists to treat ocular pain |
| 03/13/2002 | EP0901473B1 Piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same and a process for the preparation of the novel compounds |
| 03/13/2002 | EP0845989B1 Pain-alleviating drug composition |
| 03/13/2002 | EP0782445B1 Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence |
| 03/13/2002 | EP0764025B1 Method and medicine for alleviating jet lag |
| 03/13/2002 | EP0721342B1 Polypeptides of the semaphorin gene family |
| 03/13/2002 | EP0596897B1 Hydroisoquinoline derivatives |
| 03/13/2002 | CN1340103A Complex-forming proteins |
| 03/13/2002 | CN1340098A Astrocytes, their preparation and use thereof |
| 03/13/2002 | CN1340058A Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 03/13/2002 | CN1340049A 4-heterocyclylsulfonamide)-5-methoxy-6-(2-methoxyphenoxy)-2-phenyl-or-pyridylpyrimidines as endothelin receptor antagonists |
| 03/13/2002 | CN1340045A 5-HTIF agonists |
| 03/13/2002 | CN1340044A Nervinolin derivatives |